MX2009008914A - Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. - Google Patents

Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Info

Publication number
MX2009008914A
MX2009008914A MX2009008914A MX2009008914A MX2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A
Authority
MX
Mexico
Prior art keywords
metalloproteins
antibodies
pharmaceutical compositions
compositions containing
inhibiting activity
Prior art date
Application number
MX2009008914A
Other languages
English (en)
Spanish (es)
Inventor
Irit Sagi
Tamar Danon
Netta Sela
Abraham Shanzer
Rina Arad-Yellin
Raghavendra Kikkeri
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2009008914A publication Critical patent/MX2009008914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009008914A 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. MX2009008914A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90285407P 2007-02-23 2007-02-23
PCT/IL2008/000230 WO2008102359A1 (en) 2007-02-23 2008-02-21 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
MX2009008914A true MX2009008914A (es) 2009-08-28

Family

ID=39534848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008914A MX2009008914A (es) 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Country Status (11)

Country Link
US (5) US8324355B2 (enExample)
EP (1) EP2155691B1 (enExample)
JP (2) JP5513130B2 (enExample)
KR (1) KR20090113908A (enExample)
CN (1) CN101702906B (enExample)
BR (1) BRPI0807256A2 (enExample)
CA (1) CA2678304A1 (enExample)
IL (2) IL224120A (enExample)
MX (1) MX2009008914A (enExample)
RU (1) RU2503682C2 (enExample)
WO (1) WO2008102359A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155691B1 (en) * 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
EP2262840A4 (en) * 2008-03-03 2012-08-08 Dyax Corp METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS
WO2010101628A2 (en) * 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
CA2787311C (en) 2010-01-27 2017-08-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
CN104530238B (zh) 2010-08-27 2019-11-26 吉利德生物制剂公司 基质金属蛋白酶9的抗体
US10066024B2 (en) 2010-10-28 2018-09-04 Yeda Research And Development Co. Ltd. Methods of generating antibodies to metalloenzymes
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
AU2013203619B2 (en) 2012-02-29 2015-02-26 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
US10527619B2 (en) 2013-06-07 2020-01-07 Massachusetts Institute Of Technology Affinity-based detection of ligand-encoded synthetic biomarkers
TWI750108B (zh) 2014-04-03 2021-12-21 瑞士商Ｃｓｌ貝林股份有限公司 免疫球蛋白之霧化
US11357022B2 (en) 2014-05-19 2022-06-07 Qualcomm Incorporated Apparatus and method for interference mitigation utilizing thin control
US10278178B2 (en) 2014-05-19 2019-04-30 Qualcomm Incorporated Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP3424168B1 (en) * 2016-04-04 2022-06-01 Samsung Electronics Co., Ltd. Method and apparatus for transmitting and receiving feedback in wireless communication system
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2025075789A1 (en) * 2023-10-03 2025-04-10 Merck Sharp & Dohme Llc Immunoassay for detecting tau phosphorylated at serine 413
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP3348725B2 (ja) 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
WO1995029689A1 (en) 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
KR100231230B1 (ko) 1995-08-08 1999-11-15 우에노 도시오 히드록삼산 유도체(hydroxamic acid derivatives)
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
JP4358908B2 (ja) 1996-01-02 2009-11-04 アヴェンティス ファーマシューティカルズ インコーポレイテッド 置換（アリール、ヘテロアリール、アリールメチル又はヘテロアリールメチル）ヒドロキサム酸化合物
EP0994104A4 (en) 1996-06-27 2001-09-12 Ono Pharmaceutical Co ARYL SULFIDE, SULFOXIDE AND SULPHONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM AS AN ACTIVE INGREDIENT
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
PT1100792E (pt) 1998-07-30 2004-08-31 Warner Lambert Co Sulfonamidas triciclicas e seus derivados como inibidores de metaloproteinases da matriz
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
US7524938B2 (en) * 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2155691B1 (en) * 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2787311C (en) 2010-01-27 2017-08-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins

Also Published As

Publication number Publication date
WO2008102359A1 (en) 2008-08-28
US9416195B2 (en) 2016-08-16
AU2008218525A1 (en) 2008-08-28
US9902783B2 (en) 2018-02-27
US20180134808A1 (en) 2018-05-17
CN101702906A (zh) 2010-05-05
US20100233188A1 (en) 2010-09-16
US20160257765A1 (en) 2016-09-08
JP2010519289A (ja) 2010-06-03
US20130030158A1 (en) 2013-01-31
RU2503682C2 (ru) 2014-01-10
US8324355B2 (en) 2012-12-04
US8486653B2 (en) 2013-07-16
JP5792231B2 (ja) 2015-10-07
RU2009132006A (ru) 2011-02-27
IL224121A (en) 2016-05-31
EP2155691B1 (en) 2016-01-13
IL224120A (en) 2016-05-31
BRPI0807256A2 (pt) 2014-07-22
EP2155691A1 (en) 2010-02-24
JP5513130B2 (ja) 2014-06-04
US20130224225A1 (en) 2013-08-29
JP2013241435A (ja) 2013-12-05
CN101702906B (zh) 2014-02-12
CA2678304A1 (en) 2008-08-28
WO2008102359A9 (en) 2009-05-22
KR20090113908A (ko) 2009-11-02

Similar Documents

Publication Publication Date Title
MX2009008914A (es) Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.
BRPI0513990A (pt) composições de silano, processos para suas preparações e composições de borracha contendo as mesmas
NO20091706L (no) Inhibitorer av hepatitt C virus
ATE296797T1 (de) N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
ATE427932T1 (de) 11beta-hsd1-inhibitoren
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
EA200700699A1 (ru) Ингибиторы взаимодействия между mdm2 и p53
IL189466A0 (en) Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
EA201171328A1 (ru) Производное замещенного изохинолина
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
NO20091707L (no) Inhibitorer av hepatitt C virus
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
DE60123674D1 (de) Perylenpigmentzusammensetzungen
PT1951747E (pt) Processo e intermediários para a síntese de caspofungina
ATE503746T1 (de) Neue imidazolidinderivate
WO2006060424A3 (en) Inducible nitric oxide synthase dimerization inhibitors
EP1961734A4 (en) AMINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES
TW200716089A (en) BCRP/ABCG2 inhibitor
DE602004003948D1 (de) Herstellung von 2-18f-2-desoxy-d-glucose durch festphasensynthese
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
WO2006103101A3 (en) MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
WO2004103967A3 (en) Thiocarbamate inhibitors of alpha-4 integrins
IL196085A0 (en) Cyclic amine compounds and pharmaceutical compositions containing the same
SG146692A1 (en) Melanin concentrating hormone antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal